Army Europe chief unveils NATO eastern flank defense plan
As part of the plan to counter Russian threats and enable scalable, global deterrence, the Army and its NATO allies are urgently developing standardized, data-driven systems, common launchers and cloud-based coordination, according to Gen. Christopher Donahue.
Regional plans have been coming together for some time, but the Army, along with NATO, is first focusing on the Baltic states 'to try to get to how do you actually make it so that industry and the nations know exactly what the requirements are — ultimately that is now known as the Eastern Flank Deterrence Line,' Donahue said.
'We know what we have to develop and the use case that we're using is you have to [deter] from the ground,' he said. 'The land domain is not becoming less important, it's becoming more important. You can now take down [anti-access, aerial-denial] A2AD bubbles from the ground. You can now take over sea from the ground. All of those things we are watching happen in Ukraine.'
For example, Donahue noted, Kaliningrad, Russia, is roughly 47 miles wide and surrounded by NATO on all sides and the Army and its allies now have the capability to 'take that down from the ground in a timeframe that is unheard of and faster than we've ever been able to do.'
'We've already planned that and we've already developed it. The mass and momentum problem that Russia poses to us … we've developed the capability to make sure that we can stop that mass and momentum problem," Donahue said.
The plan includes a system to share data. NATO has already procured that system, Donahue said, referencing its choice of Palantir's Maven Smart System, an artificial intelligence platform from Palantir that takes a vast amount of data and rapidly analyzes information to help military commanders make decisions.
'We already know exactly what we have to do with cloud and we know exactly the type of actual unmanned systems, brigades, everything else that we need for that,' Donahue said.
Specifically, the Army wants these capabilities to be interoperable with NATO partners.
The Army also wants a common launcher that serves in both an offensive and defensive capacity, along with a fire control system that any nation can use.
And, Donahue said, 'We want everything to be optionally manned,' whether that is an air defense or a long-range fires system.
'We want it to be one system, optionally manned, where we'll be able to take munitions from any country and shoot through them,' he said.
And the Army wants to lower the cost of systems.
'As a general rule, whatever you're shooting at, whatever your weapon system or munition you shoot at, another adversary's capability, it should be cheaper than what you're shooting,' Donahue stressed.
Donahue acknowledged the obvious existence of bureaucracy but said that on the U.S. side, reform in things like foreign military sales is coming and the Army will be able to move at a much faster rate.
Directly addressing industry, Donahue said, 'We have sent a clear demand signal to you of exactly what we need. … If you sell us something, it has to be interoperable. You have to share the [Application Programming Interface]. The cost has to go down.'
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Pfizer (PFE) Receives CHMP Recommendation For Adapted COVID-19 Vaccine COMIRNATY
BioNTech SE and Pfizer recently received a positive recommendation from the European Medicines Agency for marketing authorization of their COVID-19 vaccine, which likely contributed to Pfizer's share price increase of 8% in the last quarter. The company's advancements in COVID-19 vaccine development, alongside other product-related announcements like the XTANDI and BRAFTOVI trial results, added weight to this upward movement. Despite legal challenges and declining earnings, Pfizer's focus on innovation and strategic partnerships like the one with XtalPi possibly countered broader market moves, which saw a smaller 1% increase in the same period. We've identified 3 warning signs for Pfizer that you should be aware of. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent positive recommendation from the European Medicines Agency for the COVID-19 vaccine developed by BioNTech SE and Pfizer has contributed to an 8% increase in Pfizer's share price over the last quarter. This news may provide a temporary boost to Pfizer's revenue and earnings forecasts, especially as the company continues to innovate amidst legal challenges and declining earnings. The authorization could enhance immediate market confidence in Pfizer's product pipeline, impacting future revenue projections positively. Over the past year, Pfizer experienced a total return of 13.78% including dividends, reflecting a challenging period for shareholders. When compared to the broader US market's return of 17.2% over the same period, Pfizer has underperformed, highlighting investor concerns over competitive pressures and revenue growth prospects. The current share price movement toward the analyst consensus price target of $29.23 suggests a cautiously optimistic outlook among some market participants. Analysts' revenue forecasts reflect potential declines due to increased competition for existing products, yet others anticipate that strategic shifts in research focus, especially in oncology, might mitigate future earnings risks. With a modest increase of 8% in shares largely tied to vaccine authorization, it underscores the uncertainty surrounding longer-term performance relative to bearish analyst expectations. Understand Pfizer's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include PFE. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
4 hours ago
- Yahoo
Intel (INTC) Stock Trades Down, Here Is Why
What Happened? Shares of computer processor maker Intel (NASDAQ:INTC) fell 9.6% in the afternoon session after the company reported an unexpected second-quarter loss and announced significant restructuring plans, including major job cuts. While the chipmaker's revenue of roughly $12.8 billion beat forecasts, it posted an adjusted loss of $0.10 per share, which missed Wall Street's expectations for a small profit. In response to the results, Intel announced major cost-cutting measures, including plans that involved a 15% reduction of its global workforce and the cancellation of chip factory projects in Germany and Poland. New CEO Lip-Bu Tan stated the company had "invested too much, too soon—without adequate demand." The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Intel? Access our full analysis report here, it's free. What Is The Market Telling Us Intel's shares are extremely volatile and have had 35 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 4 days ago when the stock gained 3.2% on the news that Stifel raised its price target on the company, adding to investor optimism ahead of its quarterly earnings report this week. Stifel lifted its price target on Intel to $24.50 from $21.00, while maintaining a "Hold" rating on the shares. The move comes as investors and analysts keenly await the company's second-quarter results. According to the analyst note, investor focus will likely be on the company's long-term strategy, including updates on its advanced 18A and 14A chip production processes and efforts to restructure its portfolio. Intel is up 1.8% since the beginning of the year, but at $20.58 per share, it is still trading 34.4% below its 52-week high of $31.35 from July 2024. Investors who bought $1,000 worth of Intel's shares 5 years ago would now be looking at an investment worth $415.17. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
4 hours ago
- Yahoo
Bayern Munich's Adam Aznou scheduled for Everton medical this weekend
Everton should be able to wrap up a purchase of Bayern Munich fullback Adam Aznou soon. Sport Bild reports that the 19-year-old has indeed lodged a transfer request with his Bundesliga club. Earlier this week, Kicker confirmed that Bayern's previous negotiations with Getafe CF had produced nothing but a busted deal, Fabrizio Romano now reports that the German and English club have reached full agreement on the transfer. Romano confirms numbers originating in a report from The Athletic earlier today. Bayern shall receive a base-transfer-fee for their young talent. An additional €3m in bonuses have beeb tacked on. Aznou, per Romano, will undergo his Everton medical this weekend. Aznou was recalled by Bayern Munich early from his recent loan stint with Real Valladolid in order to participate in the recent club World Cup. The teenager nevertheless wasn't able to take advantage of the opportunity accorded to him. Aznou logged only eight minutes as a substitute in Bayern's opening group stage fixture. GGFN |